scholarly journals Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient

2019 ◽  
Vol 12 (3) ◽  
pp. 709-714 ◽  
Author(s):  
Martina Napolitano ◽  
Lucia Trudu ◽  
Federica Bertolini
Keyword(s):  
Quality Of Life ◽  
Head And Neck ◽  
Checkpoint Inhibitors ◽  
Acquired Resistance ◽  
Previous Treatment ◽  
Rapid Progression ◽  
Line Treatment ◽  
Second Line ◽  
Clear Clinical Benefit

Prior to the advent of immune checkpoint inhibitors targeting PD-1/PD-L1 axis no drug demonstrated to improve survival or quality of life in the second-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Nivolumab appear to have a clear clinical benefit for R/M-HNSCC, based on improved survival, good toxicity profile, reduction in symptoms and improvement in overall quality of life. This benefit seems to be greater for PD-L1 positive patients and independent of previous treatment, even being observed among heavily pre-treated patients. However, even in responding tumors acquired resistance to nivolumab usually occurred, limiting the drug’s activity. We report a case of unexpected prolonged stable disease in second-line treatment with nivolumab after a rapid progression disease under first-line chemotherapy in biomarker-positive R/M-HNSCC.

Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors

2021 ◽  
Author(s):  
Cuc Thi Thu Nguyen ◽  
Binh Thanh Nguyen ◽  
Thuy Thi Thu Nguyen ◽  
Fabio Petrelli ◽  
Stefania Scuri ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Influential Factors ◽  
Line Treatment ◽  
Second Line

scholarly journals Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

2012 ◽  
Vol 5 (1) ◽  
Author(s):  
Mark S Walker ◽  
Elaine Yu Pharm ◽  
Jiandong Kerr ◽  
Yeun Mi Yim ◽  
Edward J Stepanski ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Symptom Burden ◽  
Line Treatment ◽  
Second Line

scholarly journals Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy

ESMO Open ◽  
2018 ◽  
Vol 3 (5) ◽  
pp. e000411 ◽  
Author(s):  
Takayuki Yoshino ◽  
Eiji Oki ◽  
Hiroaki Nozawa ◽  
Takako Eguchi-Nakajima ◽  
Hiroya Taniguchi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Overall Survival ◽  
Phase Ii ◽  
Response Rate ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Secondary Endpoints

BackgroundTrifluridine/tipiracil is an oral agent approved for the treatment of patients with metastatic colorectal cancer (mCRC). Trifluridine is an antineoplastic thymidine analogue, and tipiracil improves its bioavailability. A phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with refractory mCRC demonstrated promising efficacy results with mild toxicity profile. It is important that quality of life be preserved in patients with mCRC without compromising their prognosis. Here, we outline the TRiflUridine/tipiracil in Second-line sTudY phase II/III study (JapicCTI-173618), designed to demonstrate non-inferiority in overall survival of trifluridine/tipiracil plus bevacizumab compared with irinotecan, fluoropyrimidine and bevacizumab combination regimens as second-line treatment in patients with mCRC.Patients and methodsEligible patients have confirmed unresectable advanced or recurrent colorectal adenocarcinoma and have failed to respond to first-line oxaliplatin-based chemotherapy. A total of 524 patients are to be randomly assigned (1:1 ratio) to trifluridine/tipiracil plus bevacizumab or irinotecan, fluoropyrimidine and bevacizumab and stratified according to RAS status (wild type vs mutant). The primary endpoint of the phase II part is disease control rate with trifluridine/tipiracil plus bevacizumab therapy. Secondary endpoints are response rate and safety with trifluridine/tipiracil plus bevacizumab therapy. In the phase III part, the primary endpoint is overall survival, and secondary endpoints include quality of life, progression-free survival, response rate, disease control rate, safety, time to treatment failure, time to post-study treatment failure and the proportion of patients receiving post-study treatment. The first patient was enrolled in October 2017 and the study is anticipated to be completed in 2022.Clinical trial registrationJapicCTI-173618 (JapicCTI).

Sign in / Sign up

Export Citation Format

Share Document